Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : son of T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (255)	11/11/1999 7:14:00 AM
From: The Dodgy Ticker	Respond to of 673

<OT> Can anyone please tell me how income received from selling covered-call options is treated for tax purposes; i.e., is it considered immediate income, or does it lower the cost-basis of the underlying stock? Thanks in advance, and Regards, Bob

To: scaram(o)uche who wrote (255)	11/11/1999 7:48:00 AM
From: WTDEC	Respond to of 673

Rick, FYI. Best regards, Walter Thursday November 11, 6:04 am Eastern Time Company Press Release Scientists Present New Research That Supports Aphton's Anti-Gastrin Therapy For Gastrointestinal Cancers TUCSON, Ariz.--(BW HealthWire)--November 11, 1999--Aphton Corporation (Nasdaq:APHT - news) today announced new results that offer further support to the company's anti-gastrin approach in the treatment of gastric and colon cancers. During the three day Third International Conference on Gastrin, scientists from the UK presented findings from six studies that resulted from collaborative research with Aphton scientists. These presentations as well as other published scientific research continue to provide the foundation for Aphton's anti-gastrin drug as an emerging new therapy for gastrointestinal cancers. Aphton is in late-stage clinical trials treating patients with gastric (stomach), pancreatic and colorectal cancer. <SNIP> biz.yahoo.com

To: scaram(o)uche who wrote (255)	11/11/1999 9:50:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 673

Going to add a smidge of a couple of issues to "dry powder". The modest number of shares reflects my opinion that there are no glaring near-term drivers for the issues. Please don't run out and make study a priority today, as there's no significance to timing of the purchases. Current ask for both (4 and 7), Brown commissions. Still have lots of cash from the CELG money-printing press, so other ideas are still solicited. Thanks, Walter! Rick